ClearBridge Investments
CBIO icon

ClearBridge Investments’s Crescent Biopharma CBIO Stock Holding History

ClearBridge Investments’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-341
Closed -$553K – 1172
2018
Q1 		$553K Buy
+341
New +$709K ﹤0.01% 675

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments's CBIO Position: Q2 2018 in Review

ClearBridge Investments sold out of Crescent Biopharma (CBIO) in Q2 2018, closing a stake of 341 shares — an estimated $553K sold.

ClearBridge Investments first reported a position in CBIO in Q1 2018 and held it in 1 quarter. The position peaked at $553K in Q1 2018. 84 funds tracked by Wall St. Rank hold CBIO as of Q2 2018.

  • ClearBridge Investments reported no remaining Crescent Biopharma position as of Q2 2018 after selling out during the quarter.
  • ClearBridge Investments sold 341 Crescent Biopharma shares in Q2 2018, an estimated $553K.
  • ClearBridge Investments first reported a position in Crescent Biopharma in Q1 2018 and held it in 1 quarter.
  • ClearBridge Investments's Crescent Biopharma position peaked at $553K in Q1 2018.
  • 84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2018.

Based on ClearBridge Investments's 13F filing for Q2 2018, filed 14 Aug 2018.